Goldman Sachs Lifts S&P 500 Target to 5,600 by Year-End by Terry Bingman 17.06.2024 Goldman Sachs sees S&P 500's 3.1% upside; 15x P/E on strong growth. U.S. election key risk factor, impacting 3-month to ...
Madrigal Pharma Exec Sells $570K in Stock Amid Analyst Focus by Mark Eisenberg 15.06.2024 Waltermire sells 2,000 shares at $285 each, netting $570K; Madrigal Pharmaceuticals sees mixed analyst reports with H.C. Wainwright lowering its ...
LVMH: Peak Reached or More Growth Ahead? by Mark Eisenberg 05.04.2024 Invest like big funds for less than $9/month with AI-powered ProPicks. LVMH stock has surged 601% in the past decade ...
Goldman Predicts Upside for S&P 500 by Terry Bingman 28.03.2024 The hit rate of positive returns for S&P 500 dropped to 58% while the forward signal remains consistent with equal-weighted ...
Is the Stock Market Open Today? See Amended UK Trading Hours by Terry Bingman 28.03.2024 The London Stock Exchange (LSE) will have amended trading times during Easter 2024, with the market closing at 12:30pm. Morningstar's ...
Dow Jones Futures Fall: Palantir Soars, Nvidia Runs, Beware by Mark Eisenberg 07.03.2024 Dow Jones futures, S&P 500 futures, and Nasdaq futures dropped slightly overnight, but the stock market rebounded after tech sell-off ...
Major US Banks Push for Bitcoin ETF Custody Approval by John Darbie 17.02.2024 Major US banking institutions have written a joint letter to the SEC, urging for approval of spot Bitcoin ETF custodianship. ...
Unlock High Returns: The Allure of NCD IPOs for Retail Investors by Terry Bingman 14.02.2024 Non-Convertible Debenture (NCD) IPOs provide safe and stable investment opportunities for retail investors, offering higher yields and liquidity. They are ...
Airbnb Q4 Earnings: Analysts Predict Growth by Mark Eisenberg 13.02.2024 Airbnb is set to reveal impressive Q4 2023 financial results with 18% revenue growth, reaching nearly $3.4 billion, signaling a ...
AN2 Therapeutics Phase 3 Trial Pause Impacts Stock by Mark Eisenberg 12.02.2024 AN2 Therapeutics' stock rating was downgraded by Oppenheimer after pausing its Phase 3 trial. The company is reassessing and discussing ...